Abstract
Throughout millions of years of evolution, nature has supplied various organisms with a massive arsenal of venoms to defend themselves against predators or to hunt prey. These venoms are rich cocktails of diverse bioactive compounds with divergent functions, extremely effective in immobilizing or killing the recipient. In fact, venom peptides from various animals have been shown to specifically act on ion channels and other cellular receptors, and impair their normal functioning. Because of their key role in the initiation and propagation of electrical signals in excitable tissue, it is not very surprising that several isoforms of voltage-activated sodium channels are specifically targeted by many of these venom peptides. Therefore, these peptide toxins provide tremendous opportunities to design drugs with a higher efficacy and fewer undesirable side effects. This review puts venom peptides from spiders, scorpions and cone snails that target voltage-activated sodium channels in the spotlight, and addresses their potential therapeutical applications.
Keywords: Sodium channel, toxin, spider, scorpion, conus
Current Pharmaceutical Design
Title: Animal Peptides Targeting Voltage-Activated Sodium Channels
Volume: 14 Issue: 24
Author(s): Bert Billen, Frank Bosmans and Jan Tytgat
Affiliation:
Keywords: Sodium channel, toxin, spider, scorpion, conus
Abstract: Throughout millions of years of evolution, nature has supplied various organisms with a massive arsenal of venoms to defend themselves against predators or to hunt prey. These venoms are rich cocktails of diverse bioactive compounds with divergent functions, extremely effective in immobilizing or killing the recipient. In fact, venom peptides from various animals have been shown to specifically act on ion channels and other cellular receptors, and impair their normal functioning. Because of their key role in the initiation and propagation of electrical signals in excitable tissue, it is not very surprising that several isoforms of voltage-activated sodium channels are specifically targeted by many of these venom peptides. Therefore, these peptide toxins provide tremendous opportunities to design drugs with a higher efficacy and fewer undesirable side effects. This review puts venom peptides from spiders, scorpions and cone snails that target voltage-activated sodium channels in the spotlight, and addresses their potential therapeutical applications.
Export Options
About this article
Cite this article as:
Billen Bert, Bosmans Frank and Tytgat Jan, Animal Peptides Targeting Voltage-Activated Sodium Channels, Current Pharmaceutical Design 2008; 14 (24) . https://dx.doi.org/10.2174/138161208785777423
DOI https://dx.doi.org/10.2174/138161208785777423 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Information of ADME-Associated Proteins and Potential Application for Pharmacogenetic Prediction of Drug Responses
Current Pharmacogenomics Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF
Current Neurovascular Research Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Antiepileptic Drugs (AEDs) Polypharmacy Could Lead to Buried Pharmacokinetic Interactions due to CYP450
Drug Metabolism Letters Novel 3-{4-[2-Amino-4-(Substitutedphenyl)-2H-[1, 3] Oxazin/Thiazin-6-Yl} -2-Phenyl-3H-Quinazolin-4-One Derivatives as Enhancer of GABA Mediated Inhibition: Synthesis, Molecular Modeling and Pharmacological Studies
Letters in Drug Design & Discovery Pharmacotherapy of Obesity - Benefit, Bias and Hyperbole
Current Medicinal Chemistry Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies
Current Neuropharmacology Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
CNS & Neurological Disorders - Drug Targets The Paradox of Caffeine-Zolpidem Interaction: A Network Analysis
Current Drug Targets Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives
Current Pharmaceutical Design Mitochondrial Disorders in Adults
Current Molecular Medicine The Urokinase Receptor Interactome
Current Pharmaceutical Design Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Effects of Low Doses of Polyunsaturated Fatty Acids on the Attention Deficit/Hyperactivity Disorder of Children: A Systematic Review
Current Neuropharmacology Catatonia: A Brief Update
Current Psychiatry Reviews The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Preface [Hot topic: Potential Therapeutic Agents for Parkinsons Disease (Executive Editor: Masato Asanuma)]
Current Pharmaceutical Design Diagnostic Boundaries of Autism Disorder Vs Pervasive Developmental Disorder Nos Comparative Observational Study and Literature Review
Current Clinical Pharmacology Serotonin<sub>2c</sub> Receptor Constitutive Activity: In vivo Direct and Indirect Evidence and Functional Significance
Central Nervous System Agents in Medicinal Chemistry